Publicacións en colaboración con investigadores/as de University of Pennsylvania (16)

2023

  1. Identification of new risk loci shared across systemic vasculitides points towards potential target genes for drug repurposing

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 6, pp. 837-847

  2. Management of Psoriatic Arthritis in Patients With Comorbidities: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations

    The Journal of rheumatology, Vol. 50, Núm. 3, pp. 426-432

2022

  1. Psychometric properties of outcome measurement instruments for ANCA-associated vasculitis: a systematic literature review

    Rheumatology (Oxford, England), Vol. 61, Núm. 12, pp. 4603-4618

2020

  1. Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies

    ACR Open Rheumatology, Vol. 2, Núm. 10, pp. 543-554

2017

  1. A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis

    American Journal of Human Genetics, Vol. 100, Núm. 1, pp. 64-74

  2. Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy

    Scientific Reports, Vol. 7

2015

  1. A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility

    American Journal of Human Genetics, Vol. 96, Núm. 4, pp. 565-580

  2. New drugs from ancient natural foods. Oleocanthal, the natural occurring spicy compound of olive oil: A brief history

    Drug Discovery Today

2013

  1. Oleocanthal inhibits proliferation and MIP-1α expression in human multiple myeloma cells

    Current Medicinal Chemistry, Vol. 20, Núm. 19, pp. 2467-2475

2012

  1. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010

    The Lancet, Vol. 380, Núm. 9859, pp. 2197-2223

  2. Further evidence for the anti-inflammatory activity of oleocanthal: Inhibition of MIP-1α and IL-6 in J774 macrophages and in ATDC5 chondrocytes

    Life Sciences, Vol. 91, Núm. 23-24, pp. 1229-1235

  3. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010

    The Lancet, Vol. 380, Núm. 9859, pp. 2163-2196

2011

  1. Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice

    Autoimmunity Reviews, Vol. 10, Núm. 7, pp. 383-388

2010

  1. Effect of oleocanthal and its derivatives on inflammatory response induced by lipopolysaccharide in a murine chondrocyte cell line

    Arthritis and Rheumatism, Vol. 62, Núm. 6, pp. 1675-1682

  2. European league against rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies

    Annals of the Rheumatic Diseases, Vol. 69, Núm. 7, pp. 1269-1274

2004

  1. Predictors of severe liver fibrosis in HIV-infected patients with chronic hepatitis C [1] (multiple letters)

    Clinical Infectious Diseases